Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Fineline Cube May 8, 2026
Company Drug

Wuhan YZY Biopharma’s Bispecific Antibody M701 Receives NMPA Acceptance for Review in Malignant Ascites Treatment

Fineline Cube May 8, 2026
Company Drug

Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA

Fineline Cube Feb 15, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...

Company Drug

Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy

Fineline Cube Feb 15, 2023

China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...

Company Deals

Hygea Medtech Secures Series D Funding for Oncology Device Expansion

Fineline Cube Feb 15, 2023

Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...

Company Deals

CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research

Fineline Cube Feb 15, 2023

China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...

Company Deals

Shenzhen United Family Hospital Partners with GBA Medical Delegation

Fineline Cube Feb 15, 2023

Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...

Company Deals

Vincentage Raises RMB 100 Million for Innovative Drug Development

Fineline Cube Feb 15, 2023

Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...

Company Deals

Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab

Fineline Cube Feb 15, 2023

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...

Company Deals

Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC

Fineline Cube Feb 15, 2023

Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...

Policy / Regulatory

China’s NRDL Update: New Drugs Available for Online Procurement

Fineline Cube Feb 15, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) drug procurement platform has released a notice stating that...

Company Medical Device

Mindray Launches First Wireless Handheld Ultrasound System, TE Air

Fineline Cube Feb 15, 2023

China-based medical device firm Mindray (SHE: 300760) has announced the market launch of the firm’s...

Company Deals

Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development

Fineline Cube Feb 14, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine

Fineline Cube Feb 14, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...

Company Drug

Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610

Fineline Cube Feb 14, 2023

China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...

Company Drug

Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine

Fineline Cube Feb 14, 2023

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...

Company Drug

Gracell Biotechnologies Gains IND Approval for GC012F in China

Fineline Cube Feb 14, 2023

Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...

Hospital Policy / Regulatory

China’s Ministries Release Plan for Urban Medical Group Pilots

Fineline Cube Feb 14, 2023

A group of ministries led by the National Health Commission (NHC), including the National Development...

Company Deals Digital

ThinmedTech Partners with West China Hospital for CKD Digital Therapy

Fineline Cube Feb 14, 2023

ThinmedTech, a chronic disease clinical management solution provider based in Chongqing, has struck a partnership...

Company Drug

RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study

Fineline Cube Feb 14, 2023

China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...

Company Drug

Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang

Fineline Cube Feb 14, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...

Company Deals

Hengrui Pharmaceuticals Licenses SHR2554 to Treeline Biosciences

Fineline Cube Feb 13, 2023

China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced a licensing agreement with US-based Treeline Biosciences,...

Posts pagination

1 … 559 560 561 … 662

Recent updates

  • China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban
  • Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies
  • Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort
  • Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance
  • Zai Lab Reports Q1 2026 Revenue Decline Amid Zejula Impact from Centralized Procurement, Offset by Xacduro Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Company Drug

Huadong Medicine’s Asthma Drug CXG87 Receives NMPA Filing Acceptance Following Successful Phase III Trial Against Symbicort

Company

Eli Lilly Reports 56% Revenue Surge in Q1 2026 Driven by Mounjaro and Zepbound Dominance, Raises Full-Year Guidance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.